Review of Bone Modifying Agents in Metastatic Breast Cancer
Open Access
- 13 February 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cureus
- Vol. 13 (2)
- https://doi.org/10.7759/cureus.13332
Abstract
Bone is the most common site for distant metastases in breast cancer and can cause significant morbidity and mortality. Bone modifying agents (BMAs) that include bisphosphonates (BPAs) and denosumab help in decreasing and delaying skeletal-related events (SREs) associated with metastatic breast cancer. BPAs approved for use by the Food and Drug Administration (FDA) in bone metastases (BM) in the United States are pamidronate and zolendronic acid, while clodronate and ibandronate are licensed for use in other countries. Current American Society of Clinical Oncology (ASCO) guidelines recommend denosumab 120 mg subcutaneously every four weeks, or zolendronic acid 4 mg every four weeks or every 12 weeks, or intravenous pamidronate 90 mg every four weeks. Current guidelines do not recommend one BMA over another, however, zolendronic acid and denosumab were the most commonly used BMAs in population-based studies. Side effects of BMAs include acute phase reactions, hypocalcemia, nephrotoxicity, osteonecrosis of jaw, etc. While other side effects are common with both BPAs and denosumab, the latter has less nephrotoxic potential and is preferred for use in patients with renal failure. Current ASCO guidelines recommend continuing BMAs indefinitely, however, in clinical practice, this decision needs to be individualized, especially since there is no data on the impact of long-term use of BMAs. Further studies would need to be developed to develop an algorithm of SRE risk assessment and to determine which patients would benefit from BMAs.This publication has 48 references indexed in Scilit:
- Denosumab: mechanism of action and clinical outcomesInternational Journal of Clinical Practice, 2012
- American Society of Clinical Oncology Clinical Practice Guideline Update: Recommendations on the Role of Bone-Modifying Agents in Metastatic Breast CancerJournal of Oncology Practice, 2011
- Incidence of bone metastases and skeletal-related events in breast cancer patients: A population-based cohort study in DenmarkBMC Cancer, 2011
- Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind StudyJournal of Clinical Oncology, 2010
- Predicting skeletal complications in metastatic breast cancer raises challengesBreast Cancer Research and Treatment, 2010
- Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous BisphosphonatesJournal of Clinical Oncology, 2009
- Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate TherapyClinical Cancer Research, 2008
- Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapySupportive Care in Cancer, 2005
- Recommendations for Zoledronic Acid Treatment of Patients with Bone MetastasesThe Oncologist, 2005
- Risk of complications from bone metastases in breast cancer: implications for managementEuropean Journal of Cancer, 2000